References
Original article
Brown, J. E. et al. Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial. Lancet Oncol. https://doi.org/10.1016/S1470-2045(22)00793-8 (2023)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Masone, M.C. Temporary cessation versus continued TKI therapy for RCC. Nat Rev Urol 20, 198 (2023). https://doi.org/10.1038/s41585-023-00755-w
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-023-00755-w
- Springer Nature Limited